ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Abstract

ESHAP was found to be an active, tolerable chemotherapy regimen for relapsing and refractory lymphoma. Applying a prognostic model based on tumor burden and serum LDH level shows significant differences in survival in this patient population.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

“…The RRs that we have observed with GEM-P is encouraging and comparable to other salvage regimens (Velasquez et al, 1988(Velasquez et al, , 1994Moskowitz et al, 1999). Of particular importance, these responses are seen in a heavily pretreated population with several poor prognostic features such as chemo-resistant disease (Josting et al, 2000), relapse within a year (Brice et al, 1997;Guglielmi et al, 1998), advanced disease stage (Blay et al, 1998) and previous ASCT.…”

“…Regimens that are commonly employed are usually cisplatin based such as DHAP (dexamethasone, cytosine arabinoside and cisplatin) (Velasquez et al, 1988) and ESHAP (etoposide, methylprednisolone, cytosine arabinoside and cisplatin) (Velasquez et al, 1994) or utilise an ifosfamide -etoposide backbone such as ICE (ifosfamide, carboplatin and etoposide) (Moskowitz et al, 1999) or MINE (mitoguanzone, ifosfamide, vinorelbine, etoposide) (Ferme et al, 1995). Gemcitabine is a novel nucleoside analogue, which is active in solid tumours such as pancreatic, ovarian and non-small cell lung cancer (Burris et al, 1997;Manegold et al, 1997).…”

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

“…7,16 Briefly, etoposide was given at a dose of 40 mg/m 2 /day (83% of patients) or 60 mg/m 2 /day (17% of patients) as a 1 h intravenous infusion from day 1 to day 4, methylprednisolone was administered at a dose of 250-500 mg/day as a 15 min intravenous infusion from day 1 to day 4 or 5 (total dose of 1 g, 2 g, or 2.5 g in 24%, 52%, and 24% of patients, respectively), cisplatin was given at a dose of 25 mg/m 2 /day as a continuous infusion from day 1 to day 4, and 2 g/m 2 of cytarabine was given as a 2 h intravenous infusion on day 5. Rituximab (375 mg/m 2 ) was infused on day 1 (90% of patients) or day 5 (10% of patients), according to standard prescribing guidelines.…”

“…These regimens produce overall response rates of around 60%, and complete remission rates of 25% to 35%. [5][6][7][8][9] More effective salvage regimens are needed in order to maximize the number of patients in complete remission prior to ASCT.…”

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

“…However, despite this treatment, disease rapidly progressed. ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine), which is a standard salvage regimen for malignant lymphoma,15 was selected as a fifth‐line chemotherapy treatment. Shrinkage of the abdominal mass was observed after 1 cycle of ESHAP.…”